Validation of Biomarkers of Diabetic Nephropathy in Type I Diabetic Children

Type 1 Diabetes Mellitus With Diabetic Nephropathy Clinical Trial

— peeDIAB2  

Official title:

Identification and First Validation of Early Non-invasive Biomarkers of Diabetic Nephropathy in Type I Diabetic Children

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02164279
• Other study ID #: 12 356 03
• Secondary ID: 2012-A01097-36
• Status: Completed
• Start date: June 2013
• Est. completion date: May 25, 2016

Study information

• Verified date: September 2020
• Source: University Hospital, Toulouse
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

About 30 to 40% of patients suffering from type I diabetes are at risk of developing a diabetic nephropathy (DN) leading more or less rapidly to an end-stage renal disease. Nowadays, the microalbuminuria is the most often used clinical parameter for possible onset of DN. However, it is a late (because it permits to detect a renal disease already present), non-specific and low sensitive biomarker.

Therefore the main objective of this study is to identify early urinary biomarkers predictive of DN in children with type I diabetes, before the appearance of a microalbuminuria.

Description:

Once the type I diabetes is diagnosed, the speed of progression to a DN is very variable. Thus, the discovery of biomarkers able to distinguish progressor patients from non-progressor since the appearance of a microalbuminuria, is crucial in order to take care of progressor patients the earlier and to slow down the disease progression.

The investigators have shown that urine is a biological sample extremely well suited for proteome analysis with the aim to identify biomarkers of renal damages. Indeed, they were the first to analyze the urinary proteome of infant using capillary electrophoresis-coupled mass spectrometry. This technic permits to analyse the entire urinary proteome of a person in one hour.

Several laboratories tried to identify other predictive urinary biomarkers of the development of a DN in diabetic patients, but with limited success and nowadays in the clinical practice they still use the measure of the microalbuminuria. Contrary to precedent studies, the investigators develop an analysis without a priori and starting with early samples (without any signs of DN) associating the urinary peptide profile with the DN progression over 9-10 years.

This is a nested case-control study in a cohort of 317 patients constituting the urinary biological collection. (The urinary samples of a type I diabetic cohort of 317 patients seen between 2004 and 2008 have been collected.) These patients will be contacted at the end of 2012 to obtain a number of participation of 180 patients authorizing the use aposteriori of their urinary samples. Among this cohort, the investigators evaluate at 90 the number of patients with a DN defined by a dosage of microalbuminuria higher than 100 mg/L.

The primary endpoint of this study is therefore the identification of urinary biomarkers predictive of DN in type I diabetes pediatric patients.

The secondary endpoints are :

• The estimation of sensibility and specificity parameters, and the Area Under the Curve (AUC).

• The identification of factors associated with the variability of biomarkers expression such as the age at the moment of the diagnosis, the time between the diagnosis and the urinary collection, the rate of microalbuminuria, and the type of insulin used by the patient.

• And in the subgroup of patients for whom two urinary samples have been collected, the investigators want to study the urinary proteome stability in patients with no DN in 2013.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: May 25, 2016
• Est. primary completion date: May 25, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Years to 30 Years

Eligibility

Inclusion Criteria:

• Patient with a type I diabetes diagnosed before 15 years-old

• Urinary collection done 5 years after the diagnosis

• Urinary collection done without any acute intermittent pathology

• Urinary collection done without any treatment (other than diabetes treatment)

• Glomerular filtration rate = 60 mL/min at the moment of the urinary collection already done

• Informed consent obtained aposteriori for the analysis of the urinary samples collected between 2004 and 2008, and consent obtained for the analysis of urinary sample collected in 2013

Exclusion Criteria:

• Patients suffering from an autoimmune disease associated with the diabetes (vitiligo, Grave's disease, thyroiditis, pernicious anemia or Biermer's disease)

• Patient with a renal disease (other than diabetic nephropathy) at the first urinary collection (between 2004 and 2008)

• Pregnancy, because the urinary proteome and the microalbumin dosage can be modified during a pregnancy.

• Patient refusal to use urinary samples already collected

Related Conditions & MeSH terms

• Diabetes Mellitus, Type 1
• Diabetic Nephropathies
• Kidney Diseases
• Type 1 Diabetes Mellitus With Diabetic Nephropathy

Intervention

Other:
• Urinary sample collection
urinary sample collection will be done at the inclusion visit for the assessment of the microalbuminuria ( < or > than 100mg/L)

Locations

Country	Name	City	State
France	Purpan Children Hospital	Toulouse
France	Rangueil Hospital	Toulouse

Sponsors (2)

Lead Sponsor	Collaborator
University Hospital, Toulouse	Laboratory Inserm U858 Team 5 - RF-lab

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Identify predictive non-invasive urinary biomarkers	Urinary samples collection Assessment of the microalbuminuria to diagnose the diabetic nephropathy (DN)	Baseline (Inclusion day)
Secondary	Relation of urinary markers with patient characteristics	Patients characteristics : age of the patients at the diabetes diagnosis, their age at the urinary collection, their sex, the time between the diagnosis and the urinary collection, the type of insulin used.	Baseline (Inclusion day)